Experience of Anti-Vaccinia Immunoglobulin in the United Kingdom

Sharp, J. C. M.; Fletcher, William

doi:10.1016/s0140-6736(73)92215-0

Cited by 59 publications

(29 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have de pended on data on the incidence of complications in unprotected groups and an assessment of a lessened incidence and severity of complications in patients given vaccinial immunoglobulin at the time of vaccination. The results of this survey support the conclusions reached by Kempe et al [3] and Sharp and Fletcher [7] that VIG is valuable in prophylaxis.…”

Section: Discussionsupporting

confidence: 91%

“…The only reported controlled study was under taken by Nanning [6] in the Netherlands to assess the prophylactic effect against post-vaccinial encephalitis, and this study indicated a beneficial effect despite the small dose of 2 ml. Subsequently, studies by Sussman and Grossman [8], and Sharp and Fletcher [7] provided evidence of the efficacy of VIG in both prophylaxis and therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy of Vaccinial Immune Globulin

Feery¹

1976

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

The Efficacy of Vaccinial Immune Globulin

Feery¹

1976

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…Other dose levels or timing combinations did not significantly reduce the number of deaths. (11,14,23,25). These reports suggested a role for antibodies in the immune response to VV infection (4).…”

Section: Mtlmmentioning

confidence: 95%

Biological Activity of an Intravenous Preparation of Human Vaccinia Immune Globulin in Mouse Models of Vaccinia Virus Infection

Shearer¹,

Siemann

Gerkovich

et al. 2005

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The biological activity of a new intravenous (i.v.) preparation of human vaccinia immune globulin (VIGIV) was evaluated in two mouse models of vaccinia virus (VV) infection. In a mouse tail lesion model, female CD-1 mice were inoculated i.v. with 7 ؋ 10 4 PFU of VV to produce >10 lesions per tail 8 days later. In a mouse lethality model, female severe combined immunodeficient (SCID) mice were inoculated i.v. with 3 ؋ 10 4 PFU of VV to produce 100% mortality within 45 days. The ability of VIGIV to reduce tail lesion formation in CD-1 mice and mortality in SCID mice was determined by (i) pretreatment of a lethal VV dose with VIGIV prior to i.v. inoculation into SCID mice and (ii) i.v. administration of VIGIV to CD-1 and SCID mice the day before and up to 8 days after VV infection. VIGIV reduced the proportion of CD-1 mice with >10 tail lesions in a dose-related manner when VIGIV was given 1 day before and up to 1 day after VV inoculation. The pretreatment of VV with VIGIV prolonged survival and decreased mortality. VIGIV (100 and 400 mg/kg) prolonged survival when given up to 4 days after VV inoculation, and the 400-mg/kg dose reduced the mortality rate by 80% when given the day before or immediately after VV inoculation. The biological activity of VIGIV was demonstrated in both the immunocompetent and immunocompromised murine models. The timing of treatment relative to VV inoculation appeared to be important for the demonstration of VIGIV's biological activity.

show abstract

“…When vaccination must be given despite an obvious contraindication, human vaccinia immunoglobulin (VIG) can be used to prevent serious complications (46,118,154). Kempe et al (91) used VIG to prevent the spread of smallpox to contacts during a 1953 outbreak in Madras, India.…”

Section: Vaccinia and Smallpoxmentioning

confidence: 99%

“…Kempe et al (91) used VIG to prevent the spread of smallpox to contacts during a 1953 outbreak in Madras, India. VIG has also been used to treat complications of immunization (22,46,90,154). Recently, Kesson et al (92) used VIG and ribavirin to treat a severely immunocompromised patient who inadvertently received a vaccinia melanoma oncolysate vaccination.…”

Section: Vaccinia and Smallpoxmentioning

confidence: 99%